Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. IMNM
IMNM logo

IMNM News & Events

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

IMNM News

Immunome Q1 Earnings Beat Expectations

May 12 2026seekingalpha

Immunome Submits NDA for Varegacestat Supported by Positive Phase 3 RINGSIDE Results

Apr 29 2026Newsfilter

Immunome CSO Sells Shares Under 10b5-1 Plan

Apr 05 2026Fool

Immunome Executive Share Sale Details

Apr 05 2026NASDAQ.COM

Immunome Grants Stock Options to New Employees

Mar 05 2026Yahoo Finance

Opaleye Management Sells Entire Stake in Immunome for $37.3 Million

Mar 04 2026Fool

Opaleye Management Exits Entire Stake in Immunome

Mar 04 2026NASDAQ.COM

Immunome Reports FY Loss and Declining Revenue Amid Public Offering

Mar 03 2026seekingalpha

IMNM Events

05/31 09:20
Immunome Announces Phase 3 Trial Results for Varegacestat
Immunome announced detailed efficacy and safety results from Ringside, the global, randomized, double-blind, placebo-controlled Phase 3 trial of varegacestat in patients with progressing desmoid tumors. The data are being presented today in an oral abstract session at the 2026 American Society of Clinical Oncology, ASCO, Annual Meeting in Chicago. Immunome submitted an NDA for varegacestat to the FDA in April 2026. The Ringside trial met its primary endpoint and all key secondary endpoints. Varegacestat demonstrated a statistically significant and clinically meaningful improvement in progression-free survival, PFS, vs. placebo, with an 84% reduction in the risk of disease progression or death. The PFS benefit observed with varegacestat vs. placebo was consistent across key subgroups, including tumor location, baseline tumor size, patient age and prior systemic desmoid tumor therapy. Varegacestat achieved a statistically significant improvement in change in worst pain intensity score at week 12. Varegacestat achieved a statistically significant improvement in change in tumor volume at week 24, as assessed by blinded independent central review. Varegacestat was generally well tolerated, with a manageable safety profile consistent with the gamma secretase inhibitor class.

IMNM Monitor News

Immunome Inc experiences significant drop amid fundraising announcement

Dec 17 2025

Immunome Inc Reports Positive Phase 3 Trial Results for Varegacestat

Dec 15 2025

IMNM Earnings Analysis

No Data

No Data

People Also Watch